The purpose of this study is to evaluate the effectiveness of Leukine to decrease the need for steroid treatment for Crohn's disease.
On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
127
Once daily via subcutaneous injection for up 22 weeks
Once daily via subcutaneous injection for up 22 weeks
Corticosteroid-free remission
Time frame: At the end of the study treatment
Steroid-free remission or response to treatment as defined by the protocol
Time frame: At the end of the study treatment
Quality of Life using Inflammatory Bowel Disease Questionaire, SF 36 and EuroQol-derived visual scale (VAS)
Time frame: At the end of the study treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.